Drug Trial Radar · NCT03836040
Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine
Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
457
Actual
Start
Jul 19, 2019
Primary completion
Nov 19, 2025
Study completion Nov 17, 2026
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- Collaborators
- Novartis
- First posted
- Feb 11, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to \<12 years) and adolescents (12 to \<18 years) with episodic migraine. The study hypothesis is that in pediatric participants with episodic migraine, the combined erenumab dose group has a greater reduction from baseline to week 9 through week 12 (month 3) in monthly migraine days (MMDs) when compared with placebo in the double-blind treatment phase (DBTP).
Conditions
- Migraine
Interventions
Erenumab Dose 1Drug
Participants in the low body-weight group at day 1 and who are randomized to Dose Level 1 will receive this dose.
Erenumab Dose 2Drug
Participants in the low body-weight group at day 1 who are randomized to Dose Level 2 and subjects in the high body-weight group at day 1 who are randomized to Dose Level 1 will receive this dose.
Erenumab Dose 3Drug
Participants in the high body-weight group at day 1 who are randomized to Dose Level 2 will receive this dose.
PlaceboOther
Placebo matching dose for erenumab dose 1, 2 and 3.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in MMDsTime frame: Baseline through week 12 of the double blind treatment phase
Locations
11 sites in 4 countries. Site status is shown where the registry gives one.
Michigan Head Pain and Neurological Institute
Ann Arbor, Michigan
Docteur Simona Sava
Saint-Nicolas, Belgium
Servicios de Salud Ips Suramericana Sas - Ips Sura Industriales
Medellín, Antioquia, Colombia
Institucion Prestadora de Servicios de Salud Sociedad Médica Rionegro SA Somer SA
Rionegro, Antioquia, Colombia
Solano y Terront Servicios Medicos SAS - Unidad Integral de Endocrinologia Uniendo
Bogota, Cundinamarca, Colombia
Fundacion Hospital Infantil Universitario De San Jose
Bogota, Cundinamarca, Colombia
AthleticoMed
Bydgoszcz, Poland
Uniwersytecki Szpital Kliniczny w Poznaniu
Poznan, Poland
Clinical Research Center Spzoo Medic-R Spolka Komandytowa
Poznan, Poland
Dr Sekowska Leczenie Bolu
Warsaw, Poland
Migre Polskie Centrum Leczenia Migreny Anna Gryglas-Dworak
Wroclaw, Poland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.